e months of fiscal 2009 were $1,498.7 million, an increase of 19% over fiscal 2008. The increase was driven by the Consumer Healthcare segment and included $203.7 million of consolidated new product sales. Reported gross profit of $432.1 million was an increase of 13% over fiscal 2008, driven by the Consumer Healthcare segment. The year-to-date reported gross profit percentage in fiscal 2009 was 28.8%, down from 30.5% last year. Reported operating expenses were $240.4 million, an increase of 5% over fiscal 2008. However, as a percentage of net sales, operating expenses were 16.0%, down from 18.2% in fiscal 2008. Reported income from continuing operations was $108.8 million, relatively flat over fiscal 2008.
Consumer Healthcare segment net sales in the third quarter were $419.1 million compared with $373.0 million in the third quarter last year, an increase of $46.1 million or 12%. The increase resulted from approximately $39.2 million of sales from the acquisitions of JB Labs, Unico, Diba and Brunel, and $31.4 million from sales of new and existing products in the gastrointestinal, cough/cold, smoking cessation and nutrition categories. These increases were partially offset by the impact of unfavorable changes in foreign currency exchange rates of $12.4 million and the absence of the U.K.'s Vitamins, Minerals, and Supplements (VMS) business's sales of $9.8 million.
Reported operating income was $62.3 million, compared with $51.7 million a year ago, largely driven by a favorable mix of products sold both domestically and internationally, gross margins from sales by Unico and the absence of a $2.9 million charge to cost of sales related to the step-up in value of inventory acquired in the Galpharm acquisition that was recognized in fiscal 2008. Adjusted operating income was $63.0 million, an increase of 15% compared to a year ago.
For the first nine months of fiscal year 2Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Related medicine news :1
. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service2
. Perrigo Company to Host Analyst Meeting on September 18, 20073
. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution4
. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution5
. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory6
. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 20077
. Perrigo Company Announces Dividend Increase8
. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval9
. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference10
. Perrigo Acquires UK OTC Store Brand Supplier11
. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend